mTORbeta splicing isoform promotes cell proliferation and tumorigenesis

Area of Science:

• Cell Biology
• Molecular Oncology
• Biochemistry

Background:

• The mammalian target of rapamycin (mTOR) pathway regulates cell growth in response to nutrients and growth factors.
• While mTOR's role in energy metabolism is understood, its mechanisms in cell survival and proliferation are less clear.
• Deregulation of mTOR is implicated in various pathologies, notably cancer.

Purpose of the Study:

• To elucidate the molecular mechanisms of mTOR in mediating cell survival and proliferation.
• To identify and characterize novel mTOR splicing isoforms involved in cell cycle regulation and tumorigenesis.

Main Methods:

• Identification and characterization of the mTOR splicing isoform, TOR beta.
• Analysis of mTOR beta's protein kinase activity and its interaction with Rictor and Raptor.
• Assessment of mTOR beta's effect on cell cycle regulation and proliferation.
• In vivo tumorigenicity studies in nude mice.

Main Results:

• Discovery of the mTOR splicing isoform, TOR beta, distinct from the full-length mTOR alpha.
• TOR beta demonstrates active protein kinase function and mediates downstream signaling via Rictor and Raptor complexing.
• mTOR beta regulates the G(1) phase of the cell cycle and stimulates cell proliferation.
• Overexpression of TOR beta transforms immortal cells and exhibits tumorigenic potential in vivo.

Conclusions:

• TOR beta represents a novel, active kinase isoform of mTOR with significant roles in cell cycle control and proliferation.
• mTOR beta's ability to transform cells and induce tumors suggests its potential as a proto-oncogene in cancer development.
• Further investigation into mTOR beta signaling may reveal new therapeutic targets for cancer treatment.